A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Phase 3 Recruiting 750 enrolled Bristol-Myers Squibb BioNTech SE · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Timeline

Start: 2026-03-12
Primary completion: 2031-10-14
Completion: 2031-10-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Pembrolizumab	Monoclonal antibody	—	—
Subject	Pumitamig	Protein / enzyme biologic	—	—

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Summary

Timeline

Drugs

Indications